WP
SAGE icon

Woodline Partners’s Sage Therapeutics SAGE Stock Holding History

Woodline Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-104,831
Closed -$1.96M – 653
2024
Q1 		$1.96M Buy
+104,831
New +$2.42M 0.02% 425
2022
Q2 		– Sell
-77,866
Closed -$2.58M – 875
2022
Q1 		$2.58M Buy
+77,866
New +$2.93M 0.04% 344
2021
Q4 		– Sell
-34,813
Closed -$1.54M – 775
2021
Q3 		$1.54M Buy
+34,813
New +$1.6M 0.03% 444
2021
Q2 		– Sell
-234,434
Closed -$17.5M – 626
2021
Q1 		$17.5M Buy
234,434
+49,876
+27% +$4.09M 0.39% 75
2020
Q4 		$16M Sell
184,558
-576
-0.3% -$42.5K 0.42% 76
2020
Q3 		$11.3M Sell
185,134
-102,809
-36% -$5.21M 0.37% 80
2020
Q2 		$12M Buy
287,943
+129,116
+81% +$4.69M 0.47% 64
2020
Q1 		$4.56M Buy
158,827
+138,535
+683% +$8.02M 0.33% 90
2019
Q4 		$1.47M Buy
+20,292
New +$2.5M 0.06% 103

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Woodline Partners's SAGE Position: Q2 2024 in Review

Woodline Partners sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 104,831 shares — an estimated $1.96M sold.

Woodline Partners first reported a position in SAGE in Q4 2019 and held it in 9 quarters. The position peaked at $17.5M in Q1 2021. 195 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • Woodline Partners reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Woodline Partners sold 104,831 Sage Therapeutics shares in Q2 2024, an estimated $1.96M.
  • Woodline Partners first reported a position in Sage Therapeutics in Q4 2019 and held it in 9 quarters.
  • Woodline Partners's Sage Therapeutics position peaked at $17.5M in Q1 2021.
  • 195 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Woodline Partners's 13F filing for Q2 2024, filed 14 Aug 2024.